Skip to main content
SpringerLink
Log in

Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Lanreotide Autogel® (ATG) [Somatuline® Autogel®, Somatuline® Depot®] is a prolonged-release, supersaturated aqueous gel formulation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone and insulin-like growth factor-I levels. It is indicated for the treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. This article reviews the clinical efficacy and tolerability of lanreotide ATG in the treatment of acromegaly, as well as summarizing its pharmacological properties. Results of clinical trials and extension studies of up to 4 years duration showed that deep subcutaneous lanreotide ATG was a generally effective treatment in treatment-naive and treatment-experienced adults with acromegaly. Lanreotide ATG provided hormonal control and improved both health-related quality of life and acromegaly symptoms in most patients; it also reduced tumour volume to a clinically significant extent in studies of primary therapy. Moreover, lanreotide ATG was generally no less effective than intramuscular lanreotide long-acting microparticles and was as effective as intramuscular octreotide long-acting release in switching or crossover studies, including those with standard or extended dosing intervals. Lanreotide ATG is generally well tolerated; the most frequently reported adverse events were mild or moderate transient gastrointestinal symptoms. Lanreotide ATG also has the advantage of being available in a convenient pre-filled syringe and is given subcutaneously rather than intramuscularly. Thus, lanreotide ATG continues to be a valuable option in the treatment of acromegaly, with potential advantages being ease of administration and longer dosing intervals in patients who have an adequate response to initial therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–73.

    Article  PubMed  CAS  Google Scholar 

  2. Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011;17(Suppl 4):1–44.

    Article  PubMed  Google Scholar 

  3. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2(1):29–41.

    Article  PubMed  CAS  Google Scholar 

  4. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–17.

    Article  PubMed  CAS  Google Scholar 

  5. Feelders RA, Hofland LJ, Van Aken MO, et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. 2009;69(16):2207–26.

    Article  PubMed  CAS  Google Scholar 

  6. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8.

    Article  PubMed  CAS  Google Scholar 

  7. Ipsen Ltd. Somatuline® Autogel®, solution for injection in a pre-filled syringe: summary of product characteristics. 2011. http://www.medicines.org.uk/emc/medicine/25104/SPC/Somatuline+Autogel+60mg%2c+Somatuline+Autogel+90mg%2c+Somatuline+Autogel+120mg+New+device/. Accessed 19 June 2014.

  8. Ipsen. Somatuline® Depot (lanreotide): US prescribing information. 2013. http://somatulinedepot.com. Accessed 19 June 2014.

  9. Ministère des Affaires Sociales et de la Santé. SOMATULINE L.P. 120 mg solution for injection in a pre-filled syringe: summary of product characteristics. 2012. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=63787825&typedoc=R. Accessed 19 June 2014.

  10. Croxtall JD, Scott LJ. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs. 2008;68(5):711–23.

    Article  PubMed  CAS  Google Scholar 

  11. Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treat Endocrinol. 2004;3(2):77–81.

    Article  PubMed  CAS  Google Scholar 

  12. Patel YC, Sirikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5). Endocrinology. 1994;135(6):2814–7.

    PubMed  CAS  Google Scholar 

  13. Krejs GJ. Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motility. Scand J Gastroenterol Suppl. 1986;119:47–53.

    Article  PubMed  CAS  Google Scholar 

  14. Turner HE, Lindsell DRM, Vadivale A, et al. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol. 1999;141(6):590–4.

    Article  PubMed  CAS  Google Scholar 

  15. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–8.

    Article  PubMed  CAS  Google Scholar 

  16. Castinetti F, Saveanu A, Morange I, et al. Lanreotide for the treatment of acromegaly. Adv Ther. 2009;26(6):600–12.

    Article  PubMed  CAS  Google Scholar 

  17. Gasco V, Beccuti G, Marotta F, et al. Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients. J Endocrinol Invest. 2012;35(4):372–7.

    PubMed  CAS  Google Scholar 

  18. Steffin B, Gutt B, Bidlingmaier M, et al. Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. 2006;155(1):73–8.

    Article  PubMed  CAS  Google Scholar 

  19. Couture E, Bongard V, Maiza J-C, et al. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary. 2012;15(4):518–25.

    Article  PubMed  CAS  Google Scholar 

  20. Ning S, Knox SJ, Harsh GR, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer. 2009;16(3):1045–55.

    Article  PubMed  CAS  Google Scholar 

  21. Zatelli MC, Ambrosio MR, Bondanelli M, et al. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol. 2007;156(Suppl. 1):S29–35.

    Article  PubMed  CAS  Google Scholar 

  22. Florio T, Thellung S, Arena S, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999;141(4):396–408.

    Article  PubMed  CAS  Google Scholar 

  23. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13(1):60–7.

    Article  PubMed  CAS  Google Scholar 

  24. Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2013;99(4):1282–90.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995;80(4):1386–92.

    PubMed  CAS  Google Scholar 

  26. Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17(6):747–55.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40(1):56–68.

    Article  PubMed  CAS  Google Scholar 

  28. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.

    Article  PubMed  CAS  Google Scholar 

  29. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15(5):555–73.

    Article  PubMed  CAS  Google Scholar 

  30. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3174–9.

    Article  PubMed  CAS  Google Scholar 

  31. Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary. 1999;2(3):205–10.

    Article  PubMed  CAS  Google Scholar 

  32. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol. 1999;83(10):1506–9.

    Article  PubMed  CAS  Google Scholar 

  33. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab. 1999;84(2):527–32.

    PubMed  CAS  Google Scholar 

  34. Colao A, Marek J, Goth MI, et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008;93(6):2243–8.

    Article  PubMed  CAS  Google Scholar 

  35. Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56.

    Article  PubMed  CAS  Google Scholar 

  36. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146(3):303–9.

    Article  PubMed  CAS  Google Scholar 

  37. Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly: a prospective multi-center study. J Endocrinol Invest. 2002;25(11):971–6.

    Article  PubMed  CAS  Google Scholar 

  38. Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–50.

    Article  PubMed  CAS  Google Scholar 

  39. Cendros JM, Peraire C, Troconiz IF, et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism. 2005;54(10):1276–81.

    Article  PubMed  CAS  Google Scholar 

  40. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63(5):514–9.

    Article  PubMed  CAS  Google Scholar 

  41. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol. 2004;56(4):471–6.

    Article  PubMed  CAS  Google Scholar 

  42. Gomez-Panzani E, Chang S, Ramis J. Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Res Rep Endocr Disord. 2012;2:79–84.

    CAS  Google Scholar 

  43. Troconiz IF, Cendros J-M, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48(1):51–62.

    Article  PubMed  CAS  Google Scholar 

  44. Shimatsu A, Teramoto A, Hizuka N, et al. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013;60(5):651–63.

    Article  PubMed  CAS  Google Scholar 

  45. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–8.

    Article  PubMed  CAS  Google Scholar 

  46. Lombardi G, Minuto F, Tamburrano G, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest. 2009;32(3):202–9.

    Article  PubMed  CAS  Google Scholar 

  47. Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60(6):734–40.

    Article  PubMed  CAS  Google Scholar 

  48. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99–104.

    Article  PubMed  CAS  Google Scholar 

  49. Lucas T, Astorga R, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf). 2006;65(3):320–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Chanson P, Borson-Chazot F, Kuhn J-M, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69(2):299–305.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  51. Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18–28.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  52. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67(4):512–9.

    PubMed  CAS  Google Scholar 

  53. Schopohl J, Strasburger CJ, Caird D, et al. Efficacy and acceptability of lanreotide Autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011;119(3):156–62.

    Article  PubMed  CAS  Google Scholar 

  54. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151(3):317–24.

    Article  PubMed  CAS  Google Scholar 

  55. Caron P, Cogne M, Raingeard I, et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64(2):209–14.

    Article  PubMed  CAS  Google Scholar 

  56. Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp Clin Endocrinol Diabetes. 2005;113(3):139–44.

    Article  PubMed  CAS  Google Scholar 

  57. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008;68(3):473–80.

    Article  PubMed  CAS  Google Scholar 

  58. van der Lelij A-J, Pronin V, Balcere I, et al. Efficacy and safety of lanreotide Autogel 120 mg at extended dosing intervals in acromegalic patients biochemically controlled with octreotide LAR 10 or 20 mg: the LEAD study [abstract no. P912]. 16th European Congress of Endocrinology, Wrocław; 3–7 May 2014.

  59. van der Lely A-J, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325–33.

    Article  PubMed  Google Scholar 

  60. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.

    Article  PubMed  CAS  Google Scholar 

  61. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61–7.

    Article  PubMed  CAS  Google Scholar 

  62. Mao Z-g, Zhu Y-h, Tang H-l, et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010;162(4):661–6.

    Article  PubMed  CAS  Google Scholar 

  63. Lucas T, Astorga R, Catala M, et al. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf). 2003;58(4):471–81.

    Article  PubMed  CAS  Google Scholar 

  64. Abrams P, Alexopoulou O, Abs R, et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol. 2007;157(5):571–7.

    Article  PubMed  CAS  Google Scholar 

  65. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary. 1999;1(2):115–20.

    Article  PubMed  CAS  Google Scholar 

  66. Boyd AE, DeFord LL, Mares JE, et al. Improving the success rate of gluteal intramuscular injections. Pancreas. 2013;42(5):878–82.

    Article  PubMed  CAS  Google Scholar 

  67. Bevan JS, Newell-Price J, Wass JAH, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  68. Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  69. Salvatori R, Woodmansee WW, Molitch M, et al. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. 2013;17(1):13–21.

    Article  PubMed Central  Google Scholar 

  70. Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  71. Orlewska E, Kos-Kudla B, Sowinski J, et al. Assessment of real-world usage of lanreotide Autogel 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study. Contemp Oncol (Pozn). 2013;17(5):460–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  72. Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl). 2012;5:39–44.

    PubMed  PubMed Central  Google Scholar 

  73. Valentim J, Passos V, Mataveli F, et al. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol. 2008;52(9):1452–60.

    Article  PubMed  Google Scholar 

  74. Gadelha M, Bronstein M, Brue T, et al. Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA) [abstract no. P907]. 16th European Congress of Endocrinology, Wrocław; 3–7 May 2014.

  75. Chiasma I. Efficacy and safety of oral Octreolin™ in patients with acromegaly who are currently receiving parenteral somatostatin analogs [ClinicalTrials.gov identifier NCT01412424]. US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT01412424. Accessed 19 June 2014.

  76. Aspireo Pharmaceuticals. Somatoprim. 2014. http://www.aspireopharma.com/somatoprim/. Accessed 19 June 2014.

  77. Garrido MJ, Cendros J-M, Ramis J, et al. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. J Clin Pharmacol. 2012;52(4):487–98.

    Article  PubMed  CAS  Google Scholar 

  78. Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51(5):611–8.

    Article  PubMed  CAS  Google Scholar 

  79. Cappelli C, Gandossi E, Agosti B, et al. Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration. Endocr J. 2004;51(6):517–20.

    Article  PubMed  CAS  Google Scholar 

  80. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Celeste Burness, Sohita Dhillon and Susan Keam are salaried employees of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Celeste B. Burness, Sohita Dhillon & Susan J. Keam

Authors
  1. Celeste B. Burness
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celeste B. Burness.

Additional information

The manuscript was reviewed by: M. Bronstein, University of Sao Paulo Medical School, Sao Paulo, Brazil; P. Chanson, Publique-Hôpitaux de Paris, Hospital Bicetre and University Paris XI, Le Kremlin-Bicetre, France; A. L. Kennedy, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burness, C.B., Dhillon, S. & Keam, S.J. Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly. Drugs 74, 1673–1691 (2014). https://doi.org/10.1007/s40265-014-0283-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0283-8

Keywords

Search

Navigation